GEMoaB GmbH is a privately-owned, clinical-stage biopharmaceutical company based in Dresden, Germany, that is focused on becoming a leading, fully integrated biopharmaceutical company. By focusing on our proprietary next generation UniCAR, RevCAR and TCE platforms, we intend to discover, develop, manufacture and commercialize next generation immunotherapies for the treatment of cancer patients with a high unmet medical need.